Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial

Rationale: The combination of lumacaftor (LUM) and ivacaftor (IVA) is an approved CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator treatment for homozygous F508del patients with CF. Objectives: To evaluate the effectiveness of LUM/IVA in children (6 yr or more) and adults (m...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Am Thorac Soc
Main Authors: Sagel, Scott D., Khan, Umer, Heltshe, Sonya L., Clancy, John P., Borowitz, Drucy, Gelfond, Daniel, Donaldson, Scott H., Moran, Antoinette, Ratjen, Felix, VanDalfsen, Jill M.
Format: Artigo
Jezik:Inglês
Izdano: American Thoracic Society 2021
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7780982/
https://ncbi.nlm.nih.gov/pubmed/32644818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1513/AnnalsATS.202002-144OC
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki